Assembly Biosciences Inc (ASMB)

Assembly Biosciences, Inc. (ASMB) is a clinical-stage biotechnology company focused on applying their expertise and pioneering technologies to revolutionize treatment protocols for a wide range of chronic diseases. The company was established in 2005 and is headquartered in South San Francisco, California with additional offices in Indiana and China. It is best known for its groundbreaking work in hepatology, specifically in development of novel, class-leading therapeutics for patients with viral and non-viral liver diseases.

The principal product candidates of Assembly Biosciences are rooted in its proprietary microbiome platform, which is designed to target the gastrointestinal tract in order to address serious diseases. The company's largest drug development programs are in hepatitis B virus (HBV) and dysfunction related to the microbiome.

In its HBV program, Assembly Biosciences is developing a robust pipeline of core inhibitor candidates - a new class of HBV treatment that directly targets the HBV core protein, a fundamental aspect of the virus’ biology. These core inhibitors have been shown to produce a new curative approach to HBV, with the potential to increase cure rates significantly when added to current standard therapy.

In its microbiome program, Assembly Biosciences aims to develop and commercialize innovative treatments that modify the microbiome to address diseases and conditions that are currently underserved by existing therapies. A significant player in this program is the oral therapeutic candidate, ABI-M201, that is designed to decrease systemic inflammation by targeting the GI tract to improve the health of patients with ulcerative colitis.

Apart from its core product development, Assembly Biosciences is also invested in the research and development of other pharmaceutical products. The company is conducting collaborative preclinical research on additional hepatitis B virus core inhibitor compounds.

With a foundation built on strong science, the ongoing work of Assembly Biosciences demonstrates the potential of its approach to revolutionizing disease treatment protocols. ASMB is a publicly traded company and is listed on the NASDAQ stock exchange.

One of the key strengths of Assembly Biosciences lies in its team of seasoned industry professionals, who combine a deep understanding of microbiology and virology with an expertise in small molecule chemistry and translational medicine, providing the company a unique advantage in a competitive field. With patient-centric focus, strong partnerships and an ongoing commitment to research and development, Assembly Biosciences is poised to continue making significant strides within the biotech industry.